Tabaquismo y trastorno mental graveconceptualización, abordaje teórico y estudios de intervención

  1. Sendra Gutiérrez, Juan Manuel
  2. Casanova Peña, Bernardo
  3. Vargas Aragón, Martín L.
Aldizkaria:
Revista de la Asociación Española de Neuropsiquiatría

ISSN: 0211-5735

Argitalpen urtea: 2012

Alea: 32

Zenbakia: 116

Orrialdeak: 707-722

Mota: Artikulua

DIALNET GOOGLE SCHOLAR lock_openSarbide irekia editor

Beste argitalpen batzuk: Revista de la Asociación Española de Neuropsiquiatría

Laburpena

El hábito tabáquico es un grave problema de salud en los pacientes con trastorno mental grave. Este trabajo realiza una revisión actualizada de sus bases neurofisiológicas y abordaje terapéutico. Existe una vinculación conocida entre neurotransmisión nicotínica y esquizofrenia sin una propuesta de modelo etiológico. El abordaje terapéutico del tabaquismo en enfermos psiquiátricos requiere formación específica y unidades de tabaquismo o servicios de salud mental preparados. La asociación con consumo de sustancias tóxicas, psicofármacos, comorbilidad psiquiátrica y falta de motivación profesional constituyen factores limitantes. La intervención breve aprovecha el contacto sanitario para explorar la presencia de tabaquismo y valorar la predisposición del paciente a dejar de fumar. El tratamiento utiliza terapia sustitutiva con nicotina, antidepresivos, agonistas del receptor nicotínico y/o intervenciones psicosociales. El tratamiento con bupropion es el más efectivo y seguro, mientras la terapia sustitutiva con nicotina y la vareniclina son también útiles. En la práctica clínica la utilización de farmacoterapia y psicoterapia puede ser la opción más razonable

Erreferentzia bibliografikoak

  • (1) Buckley P. Visión clínica en esquizofrenia: consideraciones sobre la comorbilidad médica en esquizofrenia. RET Revista de Toxicomanías y Salud Mental 2009;56:3-9.
  • (2) Martínez-Ortega JM, Gurpegui M, Diaz FJ, De León J. Tabaco y esquizofrenia. Adicciones 2004;16(Supl.2):177-190.
  • (3) Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005;66:183-194.
  • (4) Hall RG, Duhamel M, McClanhan R, Miles G, Nason C, Rosen S, et al. Level of functioning, severity of illness and smoking status among chronic psychiatric patients. J Nerv Ment Dis 1995;183:468- 71.
  • (5) Prochasca JJ. Smoking and mental illness breaking the link. N Engl J Med 2011;365:196- 198.
  • (6) Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 2010;36:71-93.
  • (7) National Collaborating Centre for Mental Health commissioned by the National Institute for Health and Clinical Excellence. Schizophrenia core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). National clinical guideline n. 82. The British Psychological Society and The Royal College of Psychiatrists, 2010.
  • (8) López-Ortiz C, Roncero C, Miquel L, Casas M. Fumar en las psicosis afectivas: revisión sobre el consumo de nicotina en el trastorno bipolar y esquizoafectivo. Adicciones 2011;23:65-75.
  • (9) Molina-Linde JM. Effectiveness of smoking cessation programs for seriously mentally ill. Actas Esp Psiquiatr 2011;39:106-14.
  • (10) Hall SM, Prochasca JJ. Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. Annu Rev Clin Psychol 2009;5:409-431.
  • (11) Breslau N, Novak SP, Kessler RC. Psychiatric disorders and stages of smoking. Biol Psychiatry 2004;55:69-76.
  • (12) Kao YC, Liu YP, Cheng TH, Chou MK. Cigarette smoking in outpatients with chronic schizophrenia in Taiwan: relationships to socio-demographic and clinical characteristics. Psychiatry Res 2011, doi:10.1016/j.psychres.2011.05.016.
  • (13) Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998; 155:1490-1501.
  • (14) Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness. A Population-Based Prevalence Study. JAMA 2000; 284:2606-10.
  • (15) John U, Meyer C, Rumpf HJ, Hapke U. Smoking, nicotine dependence and psychiatric comorbidity: a population-based study including smoking cessation after three years. Drug and Alcohol Dependence 2004;76:287-295.
  • (16) Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Progress in Neurobiology 2010;92:370–385.
  • (17) Miwa JM, Freedman R, Lester HA. Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. Neuron 2011;70:20-33.
  • (18) Zammit S, Thomas K, Thompson A, Horwood J, Menezes P, Gunnell D et al. Maternal tobacco, cannabis and alcohol use during pregnancy and risk of adolescent psychotic symptoms in offspring. BJP 2009;195:294-300.
  • (19) Lester DB, Rogers TD, Blaha CD. Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neuroscience and Therapeutics 2010;16:137-162.
  • (20) Salokangas RK, Honkonen T, Stengard E, Koivisto AM, Hietala J. Cigarette smoking in long-term schizophrenia. European Psychiatry 2006;21:219-23.
  • (21) Camarelles-Guillem F, Salvador-Llivina T, Ramon-Torell JM et al. Consenso sobre la atención sanitaria del tabaquismo en España. Rev Esp Salud Publica 2009; 83:175-200.
  • (22) Raw M, McNeill A, West R. Smoking cessation guidelines for health professionals. A guide to effective smoking cessation interventions for the health care system. Thorax 1998;53(5 sup):s1-s19.
  • (23) Le Foll B, Melihan-Cheinin P, Rostoker G, Lagrue G, for the working group of AFSSAPS. Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency. European Psychiatry 2005;20:431-441.
  • (24) De Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Research 2005;76:135-57.
  • (25) Snyder M. Serious mental illness and smoking cessation. Issues Ment Health Nurs 2006;27:635-45.
  • (26) Carton S, Le Houezec J, Lagrue G, et al. Early emotional disturbances during nicotine patch therapy in subjects with and without a history of depression. J Affect Disord 2002;72:195-9.
  • (27) Brandon TH. Negative affect as motivation to smoke. Curr Dir Psychol Sci 1994;3:33-7.
  • (28) Glassman AH. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 1993;150:546-53.
  • (29) Hughes JR, Kalman D. Do smokers with alcohol problems have more difficulty quitting? Drug Alcohol Depend 2006;82:91-102.
  • (30) Lawn S, Pols R. Smoking bans in psychiatric inpatient settings? A review of the research. Aust N Z J Psychiatry 2005;39:866-85.
  • (31) Covey LS, Glassman AH, Stetner F. Cigarette smoking and major depression. J Addict Dis 1998;17:35-46.
  • (32) Killen JD, Fortmann SP, Schatzberg A, Hayward C, Varady A. Onset of major depression during treatment for nicotine dependence. Addict Behav 2003;28:461-70.
  • (33) Hughes JR. Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies, and suggestions for future research. J Consult Clin Psychol 1993;61:751-60.
  • (34) Sopelana PA. Tratamiento de la adicción al tabaco en esquizofrenia dual (cap. 10). En: Patología dual en esquizofrenia. Opciones terapéuticas. Ed. Glosa. 2007. Barcelona.
  • (35) Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; CD:000146.
  • (36) George TP, Ziedonis DM, Feingold M, Pepper WT, Satterburg CA,Winkel J, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000;157:1835-42.
  • (37) Yang YK, Nelson L, Kamaraju L, Wilson W, McEvoy JP. Nicotine decreases bradykinesiarigidity in haloperidol-treated patients with schizophrenia. Neuropsychopharmacology 2002;27:684-6.
  • (38) Hughes JR, Stead LF, Lancaster T. Antidepresivos para el abandono del hábito de fumar (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, Número 1, 2005. Oxford: Update Software Ltd. Disponible en URL: http://www.update-software.com.
  • (39) Saiz PA, García-Portilla MP, Martínez S, Bascarán MT, Paredes B, Bobes J. Tratamiento farmacológico. Psicofármacos. Adicciones 2004;16 Supl 2:275-86.
  • (40) Evins AE, Cather C, Deckersbach TH, Freudenreich O, Culhane MA, Olm-Shipman CM, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 2005;25:218-25.
  • (41) George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002;52:53- 61.
  • (42) Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166:1571-7.
  • (43) Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4 beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55.
  • (44) Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007;164:1269.
  • (45) Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007;164:1269–70.
  • (46) Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004; CD:000058.
  • (47) Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2010; CD:007253.
  • (48) Tsoi DT, Porwal M, Webster AC. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta.analysis. The British Journal of Psychiatry 2010;196:346-353.
  • (49) Jimenez-Suarez O, Castro-Alvarez E, Camacho-Oborrego S. ¿Por qué fuman tanto los esquizofrénicos?. Psiquiatria Pública 1999;11:192-195.
  • (50) Morris CD, Tedeschi GJ, Waxmonsky JA, May M, Giese AA: Tobacco Quitlines and Persons With Mental Illnesses: Perspective, Practice, and Direction. Journal of the American Psychiatric Nurses Association 2009;15:32-40.
  • (51) Dickerson FB, Tenhula WN, Green-Paden LD. The token economy for schizophrenia: review of the literature and recommendations for future research. Schizophrenia Research 2005;75:405-16.
  • (52) Practice guideline for the treatment of patients with schizophrenia. Second edition. National Guideline Clearinghouse (USA). 2004.
  • (53) McMonagle T, Sultana A. Economía de fichas para la esquizofrenia (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, número 3, 2008. Oxford, Update Software Ltd.
  • (54) Roll JM, Higgins ST, Steingard S and McGinley M. Use of monetary reinforcement to reduce the cigarette smoking of persons with schizophrenia: a feasibility study. Exp Clin Psychopharmacol 1998;6:157-61.
  • (55) El-Guebaly N, Cathcart J, Currie S, Brown D and Gloster S. Smoking cessation approaches for persons with mental illness or addictive disorders. Psychiatr Serv 2002;53:1166-70.
  • (56) Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C and Goff DC. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001;3:397-403.
  • (57) Weiner E, Ball MP, Summerfelt A, Gold J, Buchanan R. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 2001;158:635-7.
  • (58) Kisely S, Campbell LA. Use of smoking cessation therapies in individuals with psychiatric illness: an update for prescribers. CNS Drugs. 2008;22:263-73.
  • (59) Hudmon KS, Corelli RL, Prokhorov AV. Current approaches to pharmacotherapy for smoking cessation. Ther Adv Respir Dis 2010;4:35-47.
  • (60) Center for Drug Evaluation and Research. Varenicline (marketed Chantix) information: FDA alert. Rockville MD: Food and Drug Administration, 2008. Disponible en: http://www.fda.gov/Cder/ drug/infopage/varenicline/default.htm.
  • (61) West R, Baker CL, Capperelli JC, Bushmakin G. Effect of varenicline and bupoprion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychomatology 2008;197:371-377.
  • (62) Kessler RC, Berglund PA, Borges G, et al. Smoking and suicidal behaviors in the National Comorbidity Survey-Replication. J Nerv Ment Dis 2007;195:369-77.
  • (63) Ministerio de Sanidad y Consumo. Ficha técnica de Champix. Disponible en: http://sinaem4. agemed.es/consaem/fichasTecnicas.
  • (64) Cahill K, Stead L, Lancaster T. Nicotine receptor partial agonist for smoking cessation. Cochrane database Syst Rev 2007: CD006103.
  • (65) Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotine acetylcholine receptor partial agonist,vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296: 56-63.
  • (66) Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized placebo and bupropion controlled trial with 1.year follow-up. Arch Intern Med 2006;166:1561-8.
  • (67) Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-cotrolled trial of varenicline, a selective alpha4beta2 nicotinic acetyilcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29:1027-39.
  • (68) Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotine acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-cotrolled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040-56.
  • (69) Smith RC, Lindenmayer JP, Davis JM, Cornwell J, Noth K, Gupta S, Sershen H, Lajtha A. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009;110:149-55.
  • (70) Fiore MC, Jaen CR, Baker TB, et al. Clinical practice guideline: treating tobacco use and dependence: 2008 update. Rockville, MD: Department of Health and Human sevices, 2008.
  • (71) Taylor-Hays J, Ebbert JO, Sood A. Treating Tobacco Dependence in Light of the 2008 US Department of Health and Human Services Clinical Practice Guideline. Concise Review for Clinicians. Mayo Clin Proc 2009;84:730-736.
  • (72) Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2006. MMWR. 2007;56:1157–61.
Datuen iturria: Dialnet